Live Breaking News & Updates on Mariposa Study

Stay updated with breaking news from Mariposa study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

MARIPOSA: Amivantamab, Lazertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

The panel reacts to the MARIPOSA trial, which looked at amivantamab, lazertinib, and chemotherapy in the front line in patients with EGFR-mutant non–small cell lung cancer. ....

Evolving Treatment Paradigm , Advanced Non , Small Cell Lung Cancer , Non Small Cell Lung Cancer , Advanced Non Small Cell Lung Cancer , Advanced Nsclc , Nsclc Treatment , Egfr Mutant Lung Cancer , Egfr Mutated Lung Cancer , First Line Treatment , Mariposa Study ,

COMING SOON: Amivantamab + Lazertinib Versus Osimertinib as 1L Treatment in EGFR-Mutated Advanced NSCLC: Primary Results From MARIPOSA

Expert oncologist Alex Spira, MD, PhD, FACP, shares his excitement for an upcoming program centered on the MARIPOSA study in advanced NSCLC following the ESMO 2023 annual meeting. ....

Lazertinib Versus Osimertinib , Mutated Advanced , Primary Results From , Non Small Cell Lung Cancer , Advanced Nsclc , Metastatic Nsclc , Mariposa Trial , Mariposa Study , Egfr Mutated , Egfr Mutant , Combination Therapy , Novel Therapy , Egfr Tki , Tyrosine Kinase Inhibitors , Met Inhibitor , Chrysalis Study , Chrysalis Trial , Exon 20 , Egfr L858r , Efficacy Data , Overall Survival , Progression Free Survival , Pfs Data , Cns Disease , Brain Metastases , Safety Data ,